News
There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.
Bil Schmidtknecht blames pharmacy benefit managers for the death of his son. He won’t rest until he holds them accountable.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results